Boston Scientific Corporation (BSX, NYSE)
Industry: Medical Devices
Annual report, fiscal year 2009


## Now, not later.

2009 Annual Report

Boston Scientific
Delivering what's next. \( ^{™} \)




## About the photos:

The PROMUS \( ^{®} \)  Element \( ^{™} \)  Everolimus-Eluting Coronary Stent System incorporates a novel platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. On the front cover: A technician prepares PROMUS Element stents for entry into an automated spray chamber for drug application. Pictured above: A PROMUS Element stent is aligned with the balloon and prepared for crimping. On the back cover: Quality control data are scanned and captured at each stage of production.

## Sales by Geographic Segment



<table><tr><td></td><td>2009</td><td>2008</td><td>2007</td></tr><tr><td>Domestic</td><td>$4,675</td><td>$4,487</td><td>$4,522</td></tr><tr><td>EMEA</td><td>1,837</td><td>1,960</td><td>1,833</td></tr><tr><td>Japan</td><td>988</td><td>861</td><td>652</td></tr><tr><td>Asia Pacific and Americas</td><td>677</td><td>673</td><td>797</td></tr><tr><td></td><td>8,177</td><td>7,981</td><td>7,804</td></tr><tr><td>Divested businesses</td><td>11</td><td>69</td><td>553</td></tr><tr><td></td><td>$8,188</td><td>$8,050</td><td>$8,357</td></tr></table>



In 2009, Boston Scientific made substantial progress toward creating a renewed foundation for sustainable, profitable growth.

We are executing five strategic priorities that will unleash the full power of our company.

We are creating a culture of success...
now, not later.

Sales by Product Category



<table><tr><td></td><td>2009</td><td>2008</td><td>2007</td></tr><tr><td>Cardiovascular Group</td><td>$ 3,520</td><td>$ 3,563</td><td>$ 3,708</td></tr><tr><td>Cardiac Rhythm Management Group</td><td>2,562</td><td>2,439</td><td>2,271</td></tr><tr><td>Endoscopy</td><td>1,006</td><td>943</td><td>866</td></tr><tr><td>Urology and Women&#x27;s Health</td><td>456</td><td>431</td><td>403</td></tr><tr><td>Neurovascular</td><td>348</td><td>360</td><td>352</td></tr><tr><td>Neuromodulation</td><td>285</td><td>245</td><td>204</td></tr><tr><td></td><td>8,177</td><td>7,981</td><td>7,804</td></tr><tr><td>Divested businesses</td><td>11</td><td>69</td><td>553</td></tr><tr><td></td><td>$ 8,188</td><td>$ 8,050</td><td>$ 8,357</td></tr></table>



# We are creating a culture
of success, now, not later.

Despite a global recession, difficult business conditions and the disruptive debate on U.S. health care reform, we achieved successes in all our businesses in 2009. We made important progress by improving quality, launching new products and investing in our people. We accomplished a great deal that positions us well for the future.

Even so, we are far from satisfied. We understand the considerable challenges that confront us, and we see 2010 as a rebuilding year. To that end, we recently announced a series of restructuring initiatives and management changes aimed at turning around the Company.

Our job is to achieve superior results, and we will do that by creating a culture of success — now, not later. We can’t change everything overnight, but we can immediately accelerate the pace of change to deliver improved results as quickly as possible. Boston Scientific is a big ship, and it won’t be turned around in a quarter or two, but it will turn, and when it does everyone will notice.

## Strong Fundamentals

As we begin our work, we are bolstered by Boston Scientific’s remarkably strong fundamentals:

We are one of the world’s largest medical device companies, and our revenue base of more than $8 billion annually is sizable and stable.

We participate in large and growing markets that total more than $28 billion a year, and nearly all of them are larger than $1 billion.

We offer a diverse portfolio of market-leading products, and we are ranked first or second in market share in more than 75 percent of our markets.
We invest $1 billion annually in research and development, and we plan to maintain this level of investment. Our R&D efforts have consistently fueled a robust new product pipeline. In 2009, fully 42 percent of our revenue came from new products.

We have financial strength and flexibility, including exceptional cash flow. In less than three years, we have reduced our debt by more than a third, refinanced $2 billion in loan maturities and made significant progress toward achieving an investment grade profile.

## Restructuring to Achieve
Our Potential

Our restructuring initiatives and management changes will provide the organizational structure and leadership needed to execute our Strategic Plan and achieve the full potential of our Company. The changes we’re making will help us drive innovation, accelerate profitable growth and increase both management accountability and shareholder value. They will help us better serve our customers and most important, their patients.

The key components of the restructuring plan are:

Combining our Cardiovascular and Cardiac Rhythm Management groups into one stronger and more competitive organization that will improve our ability to deliver innovative products and technologies, leading clinical science and exceptional service. This new organization will be known as the CRV Group (Cardiology, Rhythm and Vascular), and it will include an Endovascular unit that will encompass Peripheral Interventions, Neurovascular, Imaging and Electrophysiology.

■ Creating the role of Chief Technology Officer. With centralized leadership we will change our allocation of resources to incorporate new growth priorities, develop technology Centers of Excellence, drive improved product development timing and efficiency, and expand the spectrum of new product opportunities.

■ Establishing new reporting relationships for the Presidents of our Endoscopy Division and our newly named Urology and Women’s Health Division. Both now report directly to the CEO, and both Divisions will attract significant additional investments.

■ Creating a Global Sales Focus team to drive targeted sales force expansions and deliver best practice capabilities in crucial areas such as training, management, forecasting and planning. This team will focus relentlessly on sales execution.

Streamlining our International organization. Three regions — Japan, Europe and a new Emerging Markets Group — now report directly to the CEO. The Emerging Markets Group will maximize our opportunities in countries whose economies and health care sectors are growing rapidly. We will focus on four key “hubs” with strong future prospects: Brazil, China, Eastern Europe and India.

In addition, we plan to further rationalize and refocus our business portfolio through select divestitures and acquisitions.

Effectiveness and efficiency must be central to everything we do. As part of our restructuring plan, over the next two years we will reduce gross expenses by $200 million to $250 million and gross head count by 1,000 to 1,300. Job loss is an unfortunate but unavoidable part of this plan. We will treat all employees affected by the reductions with dignity, respect and fairness.

Our management changes consolidate operational responsibilities under Sam Leno, Chief Operations Officer; financial responsibilities under Jeff Capello, Chief



Financial Officer, reporting to Mr. Leno; and administrative responsibilities under Tim Pratt, Chief Administrative Officer.

## Promising Opportunities

Our fundamentals are strong, we have many outstanding people, and we’ve begun a series of major steps to position our Company for long-term success. Our pipeline is the best in the industry, and it is producing a rich array of new products. We’re looking to the future with renewed optimism, and we’re excited by the promising opportunities before us.

Among our reasons for optimism are the following:

We are the undisputed share leader in the $4 billion global drug-eluting stent market. Our leadership has proved durable and resilient in the face of intense competition. We’re encouraged by our next-generation technologies such as the PROMUS \( ^{®} \)  Element \( ^{™} \)  TAXUS \( ^{®} \)  Element \( ^{™} \)  and EVOLUTION drug-eluting stent systems, and we have the industry’s only two-drug offering. We have every intention of not only maintaining but extending our leadership, both in the drug-eluting stent market and in the cath lab overall.

We hold a strong position in the $11 billion global cardiac rhythm management market. We’ve posted 10 straight quarters of growth, and we gained market share in 2009. The COGNIS \( ^{®} \)  Cardiac Resynchronization Therapy Defibrillator and the TELIGEN \( ^{®} \)  Implantable Cardiometer Defibrillator are the world’s smallest and thinnest high-energy devices. We have increased investment in our sales force and driven new product development.

■ Our Endoscopy Division reached the $1 billion milestone for worldwide sales in 2009, a tremendous accomplishment and an unmistakable sign of the potential of this business. We believe Endoscopy can double its revenues in the near future.

■ Our Urology and Women’s Health Division also has potential far beyond its current numbers. We believe this Division’s annual revenues can grow to well in excess of $1 billion. One indication of its potential is the 23 percent sales growth in its Women’s Health business from 2008 to 2009.
■ Our Neuromodulation Division saw year-over-year growth of 17 percent. The Precision Plus \( ^{™} \)  Spinal Cord Stimulation System is the only system to offer 16 independent channels, allowing more precise targeting and better treatment of chronic pain. Upcoming new product launches will contribute to continued high growth.

## POWER to Execute
Our Global Strategy

We plan to accelerate profitable growth and increase shareholder value by executing five strategic priorities, which are represented by the acronym POWER:

Prepare people and place them in strategic positions to inspire others and deliver results.

Optimize the Company for greater efficiency and effectiveness by restructuring our business model.

Win global market share by developing and acquiring high-impact growth products.

Expand our global sales and marketing focus with critical new capabilities and people so we can better execute our sales activities.

Realign our business portfolio to improve leverage and accelerate profitable growth.

We discuss these strategies in greater detail later in this report. We’re confident that these strategies, executed in pursuit of our Priority Growth Initiatives, will significantly strengthen Boston Scientific. We are deploying them now, not later, to unleash the full power of our Company.

Before closing, there are several individuals we wish to recognize. First, Jim Tobin, our CEO for 10 years, retired in 2009. During Jim’s tenure, Boston Scientific grew dramatically and helped millions of patients. We thank him for his service.

We also want to thank our departing board members for their service: Ursula Burns, Nancy-Ann DeParle, Joel Fleishman and Kristina Johnson.

We want to welcome four new board members: Katharine Bartlett, the A. Kenneth Pye Professor of Law at the Duke University School of Law; Bruce Byrnes, retired Vice Chairman of the Board for The Procter & Gamble Company; Nelda Connors, President of the Electrical and Metal Products Division of Tyco International; and John Sununu, former U.S. Senator from New Hampshire. We look forward to the benefit of their experience and counsel.

We will be tireless in our pursuit of the objectives and commitments outlined in this letter. As we do so, we will maintain the highest levels of quality, compliance and integrity. If we earn respect and trust, commercial success will follow. We are on the path to that success — now, not later.

Sincerely,



Ray Elliott
President and Chief Executive Officer



Pete Nicholas
Chairman of the Board
February 26, 2010







The PROMUS® Everolimus-
Eluting Coronary Stent System
is part of Boston Scientific’s
unique two-drug offering. We
are the undisputed global market
share leader in drug-eluting stents.

The TELIGEN® Implantable Cardioverter Defibrillator (ICD) and the COGNIS® Cardiac Resynchronization Therapy Defibrillator (CRT-D) are the world’s smallest, thinnest high-energy devices.
WallFlex® Biliary RX Stents represent the next stage in self-expandable metal stent technology.

# We have the power to lead global

## Our Five Strategic Priorities:

Our strategy is to lead global markets for less-invasive medical devices by developing and marketing innovative products, services and therapies that address unmet patient needs, provide superior clinical outcomes and demonstrate proven economic value.

The following five elements of our Strategic Plan will unleash the full power of our Company.

## Prepare...

Prepare people and place them in strategic positions to inspire others and deliver results. We will develop our people and provide them opportunities that allow them to make their greatest contributions. In particular, we will focus on talent assessment and leadership development. We will attract a world-class team. We are committed to communicating with all our employees frequently and directly, and telling them about the opportunities they have to contribute to our growth and success.

## Optimize...

Optimize the Company for greater efficiency and effectiveness by restructuring our business model. We’re restructuring and streamlining Boston Scientific. In addition, we’ve consolidated research and development under a Chief Technology Officer. We will become more efficient and effective so we can more quickly identify and capitalize on strategic opportunities.




Pinnacle® Pelvic
Floor Repair Kit devices
are part of our growing
Urology and Women's
Health Division.

The Artisan™ Surgical Lead with PlatnalLock™ technology for use with the Precision Plus™ Spinal Cord Stimulation System manages chronic neuropathic pain.

## markets...now, not later.

## Win...

Win global market share by developing and acquiring high-impact growth products. We plan to maintain our $1 billion annual research and development budget, but we will refocus our efforts to ensure we’re developing new products in line with our Priority Growth Initiatives. We recognize that we can’t achieve the growth we seek only through internal product development, so we will also look to make strategic acquisitions. We will win by providing physicians and their patients the most innovative less-invasive solutions.

## Expand...

Expand our global sales and marketing focus with critical new capabilities and people so we can better execute our sales activities. We will strengthen our sales forces worldwide to ensure customers receive the best possible service, and we will create a special focus on reaching the economic customer. Sales execution will be among our highest priorities.

## Realign...

Realign our business portfolio to improve leverage and accelerate profitable growth. We will realign our portfolio to improve our ability to market and cross sell products by specific practice areas. Physicians and hospitals will more easily see the full range of products we offer. Our CrossCare™ Program is a natural outgrowth of this strategy. It promotes mutually beneficial partnerships with our customers, helping them meet their value objectives for high-volume purchases while delivering above average growth rates for Boston Scientific.



# We are committed to
improving patient care.

Boston Scientific is widely regarded as a leader in many of the markets it serves. Yet our technology base and expertise clearly indicate that our range of opportunity is much broader. We are pursuing growth opportunities that extend into new areas not currently associated with Boston Scientific.

We are applying our less-invasive technologies to develop new products that address unmet patient needs. As we introduce these new products, we will leverage existing customer channels and relationships through our established sales forces. We estimate that many of these markets have the potential to exceed $1 billion in annual sales.

As you read the following Priority Growth Initiatives, you’ll gain a greater appreciation of our substantial potential and the essential contributions we are making to improve patient care.

## Atrial Fibrillation

Millions of individuals worldwide suffer from atrial fibrillation, a condition in which the upper chambers of the heart quiver instead of beating rhythmically. Atrial fibrillation is difficult to manage and is a leading cause of stroke and death. Atrial fibrillation is often triggered by abnormal electrical pulses originating in the four veins that return blood from the lungs to the left atrium. By cauterizing this tissue, the fibrillation can be controlled. The current technique uses radiofrequency ablation and is a long, technically demanding procedure.

We are developing a new technique using a cryogenic balloon on the end of a catheter. The balloon will freeze and isolate tissue around the four veins, a procedure that will be less demanding and require much less time than radiofrequency ablation.

## Sudden Cardiac Arrest

More than 3 million people worldwide die each year as a result of sudden cardiac arrest. Implantable cardioverter defibrillators (ICDs) use electrical pulses to help control the life-threatening irregular heartbeats that cause sudden cardiac arrest. Yet a substantial number of people who could benefit from these devices do not receive them. We are leveraging our extensive ICD technologies to explore next-generation products with a variety of features to create a new standard of effectiveness for these devices and to improve the ease of implanting them.

## Acute Ischemic Stroke

Acute ischemic strokes — those caused by obstructions in blood vessels, not by aneurysms — affect millions globally each year. We are leveraging our vascular technologies and exploring a variety of treatment options, including a stent-based treatment that would push a clot against the wall of a large vessel so that blood flow could quickly be restored. The faster blood flow is restored, the less damage to the brain. The use of a stent can also give physicians more time to consider additional treatment alternatives.

## Coronary Artery Disease

Boston Scientific is the global market share leader in drug-eluting stents. Today’s stents are coated with polymers to deliver drugs to stop the formation of scar tissue that can block arteries. New stents are being developed that will minimize the amount of polymer required to deliver therapeutic drugs. Later this year we plan to initiate a first-in-man study of a stent with a reduced amount of bioerodable polymer that is applied only to the outside of the stent and dissolves as the drug is released.








## Peripheral Vascular Disease

Peripheral vascular disease often manifests itself as a narrowing of the vessels that carry blood from the heart to the legs or kidneys. Physicians treating this disease currently lack adequate solutions for addressing peripheral vascular challenges.

We are developing a drug-coated balloon that would be inflated for about a minute and allow a drug to be transferred from the balloon to the appropriate site within the vessel. The drug would remain active for about three months to treat the blockage, and there would potentially be no need for a stent. We plan a first-in-man study of a drug-coated balloon in 2011.

## Structural Heart Disease

Most current procedures to replace or repair heart valves require open-heart surgery. The operation is intense; the recovery time is long, and certain patients are advised not to undergo this surgery. New technologies allow physicians to replace or repair aortic and mitral valves without opening the chest cavity. As is the case with stents in blood vessels, these valves can be placed in the heart through the femoral artery. Delivery technologies for percutaneous valves are a natural fit with Boston Scientific's core competencies, and we are exploring a variety of options for entering this market.

## Vascular Closure

Many less-invasive procedures, such as the placement of stents, require a leg incision to gain access to the femoral artery. Closing the arterial opening can be a time-consuming and labor-intensive process. We are working to develop a vascular closure device that will shorten and simplify this process and will be easier to use than existing products.

## Hypertension

The prevalence of hypertension is growing dramatically worldwide. Prescription drugs usually provide effective treatment, but they don’t work well for all patients. We are exploring several alternative treatments including nerve ablation and electrical stimulation, especially for those patients who do not respond to drug therapy.

## Women's Health

We are gaining a strong reputation for products used in pelvic reconstruction and in the treatment of incontinence and menorrhagia. Our less-invasive products help patients recover more quickly and return to normal, healthy lives.

We will significantly increase investment in our Women’s Health business so it can aggressively pursue the various opportunities for device-related solutions to unmet women’s health needs.



## Endoluminal Surgery

We are developing endoluminal surgical tools for abdominal procedures that would make less-invasive abdominal surgery possible and offer an alternative to laparoscopic tools. Flexible endoluminal surgical tools offer improved access and manipulation compared to current laparoscopic instruments.

## Diabetes/Obesity

Diabetes and obesity are at epidemic proportions globally. Complications from these conditions add billions to health care costs every year. We are leveraging our Endoscopy and Neuromodulation technologies to explore less-invasive treatment options that focus on endoscopic implants and electrical stimulation, and avoid highly invasive gastric bypass surgery.

## Endoscopic Pulmonary Intervention

We are exploring technologies that would help restore and increase lung function for asthma and emphysema patients. An estimated 9 million patients worldwide stand to benefit from the treatment modalities being considered by Boston Scientific.

## Deep Brain Stimulation

Our Neuromodulation products treat severe pain by sending electrical pulses to the spinal cord to mask pain signals. We are exploring the use of electrical pulses to treat a variety of other conditions including Parkinson’s disease and depression. We plan to initiate a deep brain stimulation clinical trial for Parkinson’s disease later this year.



# We are delivering a broad portfolio of innovative medical solutions worldwide.

## Cardiology, Rhythm and Vascular Group

## Major Practice Areas

Interventional Cardiology
technologies diagnose and treat
coronary artery disease and other
cardiovascular disorders.

Cardiac Rhythm Management
products treat irregular heart rhythms
and heart failure, and protect against
sudden cardiac arrest.
The Endovascular Unit encompasses
product lines in the areas of Peripheral
Interventions, Neurovascular, Imaging
and Electrophysiology.

Peripheral Interventions products treat vascular system blockages in areas such as the carotid and renal arteries and the lower extremities.

Neurovascular products treat
hemorrhagic and ischemic stroke.

Imaging products enable physicians to see inside the cardiovascular system.

Electrophysiology products use technologies such as mapping catheters, radiofrequency energy and cryogenics to diagnose and treat heart rhythm disorders.

## Endoscopy Division

## Major Practice Areas

Gastroenterology technologies
diagnose and treat diseases of the
digestive system, including the
esophagus, stomach, intestines,
pancreas, liver, gallbladder and
bile ducts.

Pulmonary products diagnose and treat diseases of the airway and lungs.

## Major Products and Procedures

Esophageal Stenting is used to relieve obstructions and strictures within the esophagus.

Duodenal and Colonic Stenting is used to treat obstructions and strictures of the small intestine and colon.

Hemostasis Control places an
endoscopic clip at a hemorrhaging
site in the digestive tract to stop
bleeding.

## Major Products and Procedures

Drug-Eluting Stents and Balloons
reopen blocked coronary arteries and
restore normal blood flow.

Catheters and Guide Wires help physicians deliver devices such as stents to treatment locations.

Pacemakers help regulate heart rates in hearts that beat too slowly.

Implantable Cardioverter
Defibrillators use electrical pulses to
help control life-threatening irregular
heart beats.

Cardiac Resynchronization
Therapy Devices treat heart failure
by improving cardiac function.

Gastrointestinal Dilation Balloons are used to open strictures within the digestive tract to allow improved swallowing and other digestive processes.

Tissue Acquisition allows physicians to remove a tissue sample or polyp from the airway or digestive tract for diagnosis.

Cholangioscopy is the examination of the bile ducts with the use of a fiber optic probe for direct visualization of the pancreatic-biliary system.
Cardiac Patient Management Systems allow physicians to remotely monitor the condition of patients implanted with cardiac rhythm management devices.

Renal Solutions use stents to restore blood flow to the kidneys.

Neurovascular Detachable Coils,
Stents, Microcatheters, Guide
Wires and Guide Catheters
offer comprehensive solutions
for brain aneurysm therapy.

Coronary Intravascular Ultrasound technology provides physicians detailed images of the heart and coronary vessels.

Cardiac Ablation neutralizes abnormal tissue that causes arrhythmias.

## Urology and Women's Health Division

## Major Practice Areas

Urology products treat kidney stones, bladder stones, urethral strictures and benign prostatic hyperplasia (BPH).

Women’s Health solutions treat
stress urinary incontinence, pelvic
floor disorders and excessive menstrual
bleeding.

## Neuromodulation Division

## Major Practice Area

Pain Management therapies use microelectronic implantable technologies to manage chronic neuropathic pain.

## Major Products and Procedures

Stone Removal products facilitate ureteroscopic and percutaneous procedures to eliminate kidney and bladder stones.

Holmium Laser Ablation of the Prostate uses laser energy to remove obstructing prostate tissue.

## Major Products and Procedures

Spinal Cord Stimulation Systems manage pain through an internal implantable pulse generator and external devices that control therapy and charge the implant.

Transurethral Microwave
Thermotherapy for BPH uses
microwave energy to reduce enlarged
tissue of the prostate.

Implantable slings and urethral bulking material are used to treat stress urinary incontinence.

## Endoscopic Retrograde

Cholangiopancreatography (ERCP) devices are used to diagnose and treat diseases of the pancreas, liver, gallbladder and bile ducts.

Enteral Feeding is used to support patients who are unable to orally ingest adequate nutrients.

Biliary Stenting is used for palliative treatment of cancers within the pancreas or bile ducts.

Pulmonary Stenting is used to open narrowed airways to allow for better breathing.

Pelvic Floor Reconstruction allows physicians to correct pelvic organ prolapse.

Endometrial Ablation uses heated saline to ablate the endometrial lining of the uterus to reduce or stop excessive bleeding.



## Board of Directors

John E. Abele
Director; Co-Founder

Katharine T. Bartlett  \( ^{2} \) 
Director; A. Kenneth Pye Professor of Law,
Duke University School of Law

Bruce L. Byrnes \( ^{1,4} \) 
Director; Retired Vice Chairman of the Board,
The Procter & Gamble Company

Nelda J. Connors  \( ^{4,5} \) 
Director; President of the Electrical and
Metal Products Division, Tyco International

## Executive Officers

Brian R. Burns
Senior Vice President, Global Quality

Jeffrey D. Capello \( ^{*} \) 
Executive Vice President and
Chief Financial Officer

Fredericus A. Colen
Executive Vice President and
Chief Technology Officer

J. Raymond Elliott  \( ^{4} \) 
President and Chief Executive Officer;
Director

 \( ^{*} \) Effective March 1, 2010

Corporate Headquarters
Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
508-650-8000
508-647-2200 (Investor Relations Facsimile)
www.bostonscientific.com

## Stockholder Information

## Stockholder Information

Stock Listing
Boston Scientific Corporation common stock is
traded on the NYSE under the symbol “BSX.”

## Transfer Agent

Inquiries concerning the transfer or exchange of shares, lost stock certificates, duplicate mailings or changes of address should be directed to the Company’s Transfer Agent at:

BNY Mellon Shareowner Services
480 Washington Boulevard
Jersey City, NJ 07310-1900
1-800-898-6713

www.bnymellon.com/shareowner/isd

Independent Registered Public Accounting Firm
Ernst & Young LLP
Boston, Massachusetts

## Annual Meeting

The annual meeting of stockholders will take place on Tuesday, May 11, 2010, beginning at 10:00 a.m. at Bank of America, 100 Federal Street, Boston, MA 02110.
J. Raymond Elliott  \( ^{4} \) 
Director; President and Chief Executive Officer

Marye Anne Fox, Ph.D. \( ^{4,5} \) 
Director; Chancellor, University of California,
San Diego

Ray J. Groves \( ^{2,3} \) 
Director; Ombudsman, Standard & Poor's;
Retired Chairman and Chief Executive
Officer, Ernst & Young

Ernest Mario, Ph.D. \( ^{1,2,5} \) 
Director; Chairman and Chief Executive
Officer, Capnia, Inc.

Joseph M. Fitzgerald
Senior Vice President and
President, Endovascular Unit

James L. Gilbert
Executive Vice President, Strategy
and Business Development

William H. Kucheman
Executive Vice President and President,
Cardiology, Rhythm and Vascular Group

Jean Fitterer Lance
Senior Vice President and
Chief Compliance Officer

Investor Information Requests
Investors, stockholders and security
analysts seeking information about
Boston Scientific should refer to our
website at www.bostonscientific.com
or call Investor Relations at 508-650-8555.

## Other Information

Copies of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports are available free of charge through our website at www.bostonscientific.com. Our Corporate Governance Guidelines, proxy statement and Code of Conduct — which apply to all our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer — are also available on our website.

Certifications of the Chief Executive Officer and Chief Financial Officer certifying the accuracy of the Company’s public disclosures have been filed with the SEC as exhibits to the Annual Report on Form 10-K for the year ended December 31, 2009.

Copies of these reports are also available by directing requests to:

Investor Relations
Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
508-650-8555
508-647-2200 (Facsimile)
Investor_Relations@bsci.com

N.J. Nicholas, Jr. \( ^{4} \) 
Director; Private Investor
Pete M. Nicholas
Director; Chairman of the Board, Co-Founder
John E. Pepper  \( ^{2,3,6} \) 
Director; Chairman of the Board of Directors,
The Walt Disney Company; Co-Chair of
Board of Directors, National Underground
Railroad Freedom Center
Uwe E. Reinhardt, Ph.D. \( ^{1,5} \) 
Director; Professor of Economics and
Public Affairs, Princeton University

Samuel R. Leno \( ^{*} \) 
Executive Vice President and
Chief Operations Officer

Andrew N. Milani II
Senior Vice President,
Human Resources

Stephen F. Moreci
Senior Vice President,
Global Sales Operations

J. Michael Onuscheck
Senior Vice President and
President, Neuromodulation Division

Corporate Social Responsibility
We are committed to supporting global,
national and local health and education
initiatives, striving to improve patient
advocacy, adhering to strong ethical standards
that deliver on our commitments, and
minimizing our impact on the environment.
Learn more by visiting
www.bostonscientific.com.

## Safe Harbor for

Forward-Looking Statements
This Annual Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Forward-looking statements include, among other things, statements regarding our growth strategy, our intentions and expectations regarding our business strategy, our programs to enhance shareholder value, our financial performance, our revenue and operating income objectives, our market position and the marketplace for our products, new product development and launch, competitive offerings, litigation and our capital management strategy. Factors that may cause actual results to differ materially from those contemplated by the statements in this Annual Report can be found in our Form 10-K for the year ended December 31, 2009, under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.”

## Warren B. Rudman 2.6

Director; Former U.S. Senator; Of Counsel, Paul, Weiss, Rifkind, Wharton & Garrison LLP; Co-Chair; Albright Stonebridge Group

John E. Sununu \( ^{3,5} \) 
Director; Former U.S. Senator

Information is accurate as of February 26, 2010.
1 Member of the Audit Committee
2 Member of the Executive Compensation and
Human Resources Committee
3 Member of the Nominating and Governance Committee
4 Member of the Finance Committee
5 Member of the Compliance and Quality Committee
6 Retiring effective May 11, 2010

John B. Pedersen
Senior Vice President and President,
Urology and Women's Health Division

Michael P. Phalen
Senior Vice President and
President, Endoscopy Division

Timothy A. Pratt
Executive Vice President,
Chief Administrative Officer,
General Counsel and Secretary

Kenneth J. Pucel
Executive Vice President, Global Operations

## In Memoriam:
Dr. Donald S. Baim



Last year we
lost our friend
and colleague
Dr. Donald S.
Baim. He was

our Chief Medical and Scientific Officer, but he was also the chief advocate and champion for millions of patients who were helped by our products, technologies and clinical science.

He was a pioneer in the development of interventional cardiology, and the many contributions he made to science, medicine and medical technology will serve as a proud and enduring legacy.

We were fortunate to have had Dr. Baim as a member of the Boston Scientific family, and we are grateful for all he did for our Company. We will create a permanent memorial to Dr. Baim with the establishment of a medical school scholarship in his name.



## Now, not later.

Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
www.bostonscientific.com

CC.AR.WW.03.10

Boston Scientific
Delivering what's next. \( ^{™} \)